EpiBone, Inc.

EpiBone, Inc. is a biotechnology startup that was founded in 2013. The company's groundbreaking approach to bone reconstruction allows patients to "grow their own bone" using their own stem cells. By leveraging a scan of the patient's bone defect, EpiBone creates a defect-specific autologous-like bone graft, offering a superior solution for over 900,000 patients undergoing bone-related surgeries annually. The company's technology aims to provide exact defect repair, simplified surgical procedures, improved bone formation and regeneration, and reduced recovery times, all without the complications of foreign body implantation. In December 2022, EpiBone secured a Venture Round investment, with participation from the Catalytic Impact Foundation and Kendall Capital Partners. Headquartered in the United States, EpiBone holds significant promise in revolutionizing bone reconstruction within the healthcare industry.